Paper - WANFANG MED ONLINE

You Position: Home > Paper

An inactivated recombinant rabies virus chimerically expressed RBD induces humoral and cellular immunity against SARS-CoV-2 and RABV

( views:2, downloads:0 )

Author:: No author available

Journal Title:: Virologica Sinica

Issue:: 2

DOI:: No doi available

Key Word:: SARS-CoV-2;Vaccine;RBD;Chimeric expression;RABV

Abstract： Many studies suggest that severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)can infect various animals and transmit among animals,and even to humans,posing a threat to humans and animals.There is an urgent need to develop inexpensive and efficient animal vaccines to prevent and control coronavirus disease 2019(COVID-19)in animals.Rabies virus(RABV)is another important zoonotic pathogen that infects almost all warm-blooded animals and poses a great public health threat.The present study constructed two recombinant chimeric viruses expressing the S1 and RBD proteins of the SARS-CoV-2 Wuhan01 strain based on a reverse genetic system of the RABV SRV9 strain and evaluated their immunogenicity in mice,cats and dogs.The results showed that both inactivated recombinant viruses induced durable neutralizing antibodies against SARS-CoV-2 and RABV and a strong cellular immune response in mice.Notably,inactivated SRV-nCoV-RBD induced earlier antibody pro-duction than SRV-nCoV-S1,which was maintained at high levels for longer periods.Inactivated SRV-nCoV-RBD induced neutralizing antibodies against both SARS-CoV-2 and RABV in cats and dogs,with a relatively broad-spectrum cross-neutralization capability against the SARS-CoV-2 pseudoviruses including Alpha,Beta,Gamma,Delta,and Omicron,showing potential to be used as a safe bivalent vaccine candidate against CO VID-19 and rabies in animals.

Reference

[1]Collier Dami A.,Ferreira Isabella A. T. M.,Kotagiri Prasanti,etc.Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2[J].2021,596(7872).
[2]Wang, Hualei,Jin, Hongli,Feng, Na,etc.Using rabies virus vaccine strain SRV9 as viral vector to express exogenous gene[J].2015,50(2).
[3]Priscilla L,Phillips,Leticia,Reyes,Edith M,Sampson,etc.Deletion of a conserved transcript PG_RS02100 expressed during logarithmic growth in Porphyromonas gingivalis results in hyperpigmentation and increased tolerance to oxidative stress.[J].2018,13(11).
[4]Young-Il,Kim,Seong-Gyu,Kim,Se-Mi,Kim,etc.Infection and Rapid Transmission of SARS-CoV-2 in Ferrets.[J].2020.
[5]van Doremalen Neeltje,Lambe Teresa,Spencer Alexandra,etc.ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques[J].2020,586(7830).
[6].Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial[J].2017,24.
[7]Giulietta Maruggi,Cuiling Zhang,Junwei Li,etc.mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases[J].2019,27(4).
[8]Matsumoto, Takashi,Yamada, Kentaro,Iha, Hidekatsu,etc.Development and evaluation of a rapid neutralizing antibody test for rabies[J].2009,161(1).
[9]Abreu-Mota Tiago,Hagen Katie R.,Cooper Kurt,etc.Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever[J].2018,9(1).
[10]Chen,Chen,Chengguang,Zhang,Ruiming,Li,etc.Monophosphoryl-Lipid A (MPLA) is an Efficacious Adjuvant for Inactivated Rabies Vaccines.[J].2019,11(12).
[11]Jianhui,Nie,Qianqian,Li,Jiajing,Wu,etc.Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.[J].2020,9(1).
[12]M J, Schnell,T, Mebatsion,K K, Conzelmann.Infectious rabies viruses from cloned cDNA.[J].1994,13(18).
[13]Christoph Wirblich,Christopher M. Coleman,Drishya Kurup,etc.One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirusand Rabies Virus[J].2017,91(2).
[14]Ning,Wang,Jian,Shang,Shibo,Jiang,etc.Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses.[J].2020,11.
[15]Willet, Mallory,Kurup, Drishya,Papaneri, Amy,etc.Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses[J].2015,212(Suppl.2).
[16]Waqas Ahmad,Yingying Li,Yidi Guo,etc.Rabies virus co-localizes with early(Rab5) and late(Rab7) endosomal proteins in neuronal and SH-SY5Y cells[J].2017,(3).
[17]L.J. REED,H. MUENCH.A Simple Method of Estimating Fifty Per Cent Endpoints,[J].1938,27(3).
[18]Correia Moreira, Beatriz Lourenc,Pereira, Luciane Aparecida,Lappas Gimenez, Ana Paula,etc.Development and validation of a real-time RT-PCR assay for the quantification of rabies virus as quality control of inactivated rabies vaccines[J].2019,270.
[19]Cliquet F,Sagne L,Aubert M.Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody.[J].1998,212(1).
[20]Lundstrom,Kenneth.Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19[J].2020,12(11).
[21]Shengnan,Zhang,Meng,Hao,Na,Feng,etc.Genetically Modified Rabies Virus Vector-Based Rift Valley Fever Virus Vaccine is Safe and Induces Efficacious Immune Responses in Mice.[J].2019,11(10).
[22]Shi Rui,Shan Chao,Duan Xiaomin,etc.A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2[J].2020,584(7819).
[23]Baz A,Grille S,Chabalgoity JA,etc.The relevance of cytokines for development of protective immunity and rational design of vaccines.[J].2007,18(1).
[24]Yang Jingyun,Wang Wei,Chen Zimin,etc.A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity[J].2020,586(7830).
[25]Entao,Li,Feihu,Yan,Pei,Huang,etc.Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice.[J].2020,12(1).
[26]Kapsenberg ML,Kalinski P,Wierenga EA,etc.Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction.[J].2000,164(9).
[27].Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens[J].2017,91(8).
[28]James P. McGettigan,Kristin Naper,Jan Orenstein,etc.Functional Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and Env Expressed from a Single Rhabdovirus-Based Vaccine Vector Genome[J].2003,77(20).
[29]Daniel,Wrapp,Nianshuang,Wang,Kizzmekia S,Corbett,etc.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.[J].2020,367(6483).